Enlicitide (Lipfendra): The First Oral PCSK9 Inhibitor for High Cholesterol
Enlicitide (Lipfendra): The First Oral PCSK9 Inhibitor for High Cholesterol
Medical Disclaimer: This article is for information only. It is not medical advice. Do not start, stop, or change any medication without talking to your doctor. Enlicitide (Lipfendra) is a prescription drug. Only your doctor can decide if it is right for you.
What Is Enlicitide?
Enlicitide (brand name: Lipfendra) is a brand-new pill that lowers bad cholesterol. The FDA approved it on July 16, 2026. It is made by Merck.
Here is why it is a big deal: it is the first-ever pill in its class. Until now, all PCSK9 inhibitors were shots you had to inject every 2 to 4 weeks. Now there is a once-a-day pill.
How Does It Work?
Your liver has tiny "garbage collectors" called LDL receptors. They grab bad cholesterol from your blood and remove it.
But your body also makes a protein called PCSK9. This protein breaks the garbage collectors. Fewer collectors = more bad cholesterol in your blood.
Enlicitide blocks PCSK9. When PCSK9 is blocked, your garbage collectors stay alive longer. They pull more bad cholesterol out of your blood. Result: lower LDL cholesterol.
The pill is a "macrocyclic peptide" — a small ring-shaped protein that fits perfectly into the PCSK9 slot and stops it from working. You take one 20 mg pill per day.
Who Is It For?
Enlicitide is for adults with high LDL cholesterol. It is meant to be used along with a healthy diet and exercise. It can help people who:
- Cannot lower their cholesterol enough with statins alone
- Cannot take statins because of side effects
- Have a genetic condition called familial hypercholesterolemia (very high cholesterol from birth)
Where Does It Stand?
| Stage | Status |
|---|---|
| Lab Discovery | ✅ Complete |
| Phase 1 (Safety) | ✅ Complete |
| Phase 2 (Dosing) | ✅ Complete |
| Phase 3 (Large Trials) | ✅ Complete (CORALreef program) |
| FDA Approval | ✅ Approved July 16, 2026 |
| Available to Patients | 🔜 Coming soon (just approved) |
Why Does This Matter?
Heart disease is the number one killer in the world. High LDL cholesterol is one of the biggest drivers of heart disease.
PCSK9 inhibitors are extremely effective. They can lower LDL cholesterol by 50-60% on top of statins. But the injectable versions (Repatha, Praluent, Leqvio) have a problem: many people do not want to take a shot every few weeks. Some cannot because of cost or logistics.
A once-daily pill changes everything. It removes the "needle barrier." More people will get access to powerful LDL-lowering. That means fewer heart attacks, fewer strokes, and longer lives.
For longevity, this is a meaningful step forward. Cholesterol management is one of the few things proven to extend healthy lifespan. A pill that makes the strongest cholesterol drugs easier to take is a real win.
What We Do Not Know Yet
- Long-term safety: The drug is brand new. We will learn more as millions of people start taking it.
- Heart attack reduction: The FDA approved it based on LDL lowering. We still need outcome trials that prove it reduces actual heart attacks and strokes (not just cholesterol numbers).
- Price: Merck has not announced the price yet. Injectable PCSK9 inhibitors can cost $5,000-$14,000 per year. If the pill is similarly priced, insurance coverage will decide who can afford it.
- Side effects: In clinical trials, side effects were similar to placebo. But real-world use always reveals more.
- Comparison to injectables: Head-to-head trials against Repatha or Leqvio have not been done yet.
The Bottom Line
Enlicitide (Lipfendra) is the first pill in a powerful class of cholesterol drugs that were previously only available as shots. It was just approved yesterday. If priced fairly and covered by insurance, it could help millions of people lower their heart attack risk — and live longer.
Sources
- FDA approves enlicitide (Lipfendra) — Merck press release, July 16, 2026
- "FDA Approves Enlicitide, an Oral PCSK9 Inhibitor, for LDL-Lowering" — TCTMD, July 16, 2026
- "FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol" — Pharmacy Times, July 16, 2026
- "Merck oral PCSK9 enlicitide shows improved cholesterol lowering vs. non-statins" — Seeking Alpha, March 30, 2026
- "Phase III Trials Show Merck's Oral PCSK9 Inhibitor Significantly Reduces LDL-Cholesterol" — Pharmaceutical Executive, June 9, 2025